Author

E. Shevchenko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. C. Joerger· 2 shared A. Kraemer· 2 shared A. Poso· 2 shared D.-I. Balourdas· 2 shared L. Elson· 2 shared L. M. Berger· 2 shared M. Rak· 2 shared R. Tesch· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. C. Joerger

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of selective pyridopyrimidin-7(8H)-one-based Mammalian STE20-like (MST3/4) kinase inhibitors

M. Rak, A. Menge, R. Tesch, L. M. Berger, D.-I. Balourdas, E. Shevchenko, A. Kraemer, L. Elson, B.-T. Berger, I. Abdi, L. M. Wahl, A. Poso, A. Kaiser, T. Hanke, T. Kronenberger, , S. Knapp

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

bioRxiv · Nov 24, 2023Biochemistry

Grubraw, a chemogenetic mitochondrial activator, reveals new mechanisms underlying the Warburg effect

E. S. Potekhina, D. Y. Bass, A. V. Ivanenko, A. A. Moshchenko, D. A. Korzhenevskiy, E. Shevchenko, A. E. Karnaeva, N. F. Zakirova, A. V. Ivanov, L. E. Shimolina, M. V. Shirmanova, O. V. Lyang, O. I. Patsap, O. M. Kudryashova, G. R. Gazizova, , V. Belousov

The paper introduces Grubraw, a chemogenetic tool that activates mitochondrial respiration in Warburg-type cancer cells, revealing that mitochondrial pyruvate export and reduced proliferation occur.

bioRxiv · Apr 18, 2023 · PreprintCancer Biology

Shifting the selectivity of pyridopyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

M. Rak, R. Tesch, L. M. Berger, E. Shevchenko, M. Raab, A. Tjaden, R. Zhubi, D.-I. Balourdas, A. C. Joerger, A. Poso, A. Kraemer, L. Elson, A. Lucic, T. Kronenberger, T. Hanke, , S. Knapp

This paper develops a selective SIK kinase inhibitor, MR22, by optimizing a pyrido[2,3-d]pyrimidin-7(8H)-one scaffold to eliminate PAK activity, demonstrating its efficacy in ovarian cancer cells.

bioRxiv · Mar 24, 2023Biochemistry

Metabolic fate of human immunoactive sterols in Mycobacterium tuberculosis

T. Varaksa, S. Bukhdruker, I. Grabovec, E. Marin, A. Kavaleuski, A. Gusach, K. Kovalev, I. Maslov, A. Luginina, D. Zabelskiy, R. Astashkin, M. Shevtsov, S. Smolskaya, A. Kavaleuskaya, P. Shabunya, , N. Strushkevich

The paper identifies Mtb enzymes that metabolize human immune oxysterols and vitamin D3 derivatives, revealing a potential drug target for tuberculosis treatment.

bioRxiv · Jul 7, 2020Biochemistry